FINWIRES · TerminalLIVE
FINWIRES

SHA:600998

4 stories mentioning SHA:600998Updated 21d ago

Every FINWIRES story that references SHA:600998, newest first.

Asia

Jointown Pharma Issues 1 Billion Yuan in Asset-Backed Securities

Jointown Pharmaceutical (SHA:600998) completed the issuance of 1 billion yuan in asset-backed securities, according to a Shanghai bourse filing on Thursday.The securities carry a coupon rate of 1.75% and mature on June 8, 2028.The issuance comprises a senior tranche worth 950 million yuan and a subordinated tranche of 50 million yuan.The Chinese pharmaceutical company's controlling shareholder, Chuchang Investment Group, subscribed to the subordinated tranche.

SHA:600998
Asia

Jointown Pharmaceutical Unit Gets Nod to Market Allergy Symptoms Treatment

Jointown Pharmaceutical's (SHA:600998) subsidiary, Beijing Jingfeng Pharmaceutical (Shandong), received approval from China's National Medical Products Administration for the marketing of its active pharmaceutical ingredient, azelastine hydrochloride, according to a Shanghai bourse filing on Wednesday.The drug is a selective histamine H1 receptor antagonist with antihistamine and anti-allergic properties.

SHA:600998
Asia

Jointown Pharma Unit Passes China Generic Drug Evaluation

Jointown Pharmaceutical (SHA:600998) unit Shandong Jingfeng passed China's generic drug consistency evaluation for trihexyphenidyl hydrochloride tablets.The anticholinergic drug is used to treat Parkinson's patients and for antipsychotic-induced extrapyramidal reactions, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 2% in recent trade.

SHA:600998
Asia

Jointown Pharmaceutical Unit Passes Shandong GMP Inspection

Jointown Pharmaceutical (SHA:600998) unit Beijing Jingfeng Pharmaceutical Shandong passed a good manufacturing practices (GMP) compliance inspection by the Shandong Medical Products Administration for its tablet production lines.The inspection covered Workshop 801, which produces metformin hydrochloride enteric-coated tablets for type 2 diabetes and isosorbide dinitrate tablets for coronary heart disease and angina, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.

SHA:600998

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:600998 in your portfolio
WheelAI
WheelAI
Analyze SHA:600998 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:600998